Patents by Inventor Bernard Gaudilliere
Bernard Gaudilliere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6962922Abstract: A compound selected from those of formula (I): wherein W1 represents O, S, or —NR3 in which R3 represents hydrogen, alkyl, OH or CN; W2 represents a group selected from hydrogen, CF3, NH2, monoalkylamino, dialkylamino, alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkylalkyl, heterocycle, these groups being optionally substituted, or W1 and W2 form together a group of formula —N?X4—W3— as defined in the description, X1, X2 and X3 represent N or C optionally substituted, n is 0 to 8, Z represents —CR12R13, wherein R12 and R13 are as defined in the description, A represents a ring system, the groups R2 represent hydrogen or various chemical groups as defined in the description, q is 0 to 7; R1 represents hydrogen, alkyl, alkenyl, alkynyl, or a ring system, and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.Type: GrantFiled: October 11, 2002Date of Patent: November 8, 2005Assignee: Warner-Lambert Company LLCInventors: Bernard Gaudilliere, Henri Jacobelli, Joseph Armand Picard, Michael William Wilson
-
Publication number: 20050245548Abstract: A compound selected from those of formula (I): wherein W1 represents O, S, or —NR3 in which R3 represents hydrogen, alkyl, OH or CN; W2 represents a group selected from hydrogen, CF3, NH2, monoalkylamino, dialkylamino, alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkylalkyl, heterocycle, these groups being optionally substituted, or W1 and W2 form together a group of formula —N?X4—W3— as defined in the description, X1, X2 and X3 represent N or C optionally substituted, n is 0 to 8, Z represents —CR12R13, wherein R12 and R13 are as defined in the description, A represents a ring system, the groups R2 represent hydrogen or various chemical groups as defined in the description, q is 0 to 7; R1 represents hydrogen, alkyl, alkenyl, alkynyl, or a ring system, and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.Type: ApplicationFiled: June 9, 2005Publication date: November 3, 2005Inventors: Bernard Gaudilliere, Henri Jacobelli, Joseph Picard, Michael Wilson
-
Patent number: 6894057Abstract: A compound selected from those of formula (I): wherein: X1, X2, and X3, represent N or —CR3 in which R3 is as described in the description, G1 represents a group selected from those of formulae (i/a) and (i/b): in which R4, R5, and R6 are as defined in the description, G2 represents a group selected from carbon—carbon triple bond, —CH?C?CH—, C?O, C?S, S(O)n1 in which n1 represents an integer from 0 to 2 inclusive, or a group of formula (i/c): in which Y1 represents O, S, —NH or -Nalkyl, and Y2 represents O, S, —NH or -Nalkyl, n is an integer from 0 to 6 inclusive, and m is an integer from 0 to 7 inclusive, Z1 represents —CR9R10, wherein R9 and R10 are as defined in the description, A represents a ring system, R1 represents a group selected from H, alkyl, alkenyl, alkynyl, optionally substituted and the group of formula (i/d): in which p, Z2, B, q and G3 are as defined in the description and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptType: GrantFiled: March 7, 2003Date of Patent: May 17, 2005Assignee: Warner-Lambert CompanyInventors: Bernard Gaudilliere, Henry Jacobelli, Catherine Kostlan, Jack Jie Li, Wen-Song Yue
-
Patent number: 6849637Abstract: A compound selected from those of formula (I): in which: W represents N or C—R1; in which R1 is as defined in the description, X represents N or C—R2 in which R2 is as defined in the description, Y represents a group selected from oxygen, sulfur, —NH, and —Nalkyl, Z represents a group selected from oxygen, sulphur, —NR8 in which R8 is as defined in the description, and optionally carbon depending the definition of Y, n is an integer from 0 to 8 inclusive, Z1 represents a group —CR9R10 wherein R9 and R10, are as defined in the description, which group contains optionally multiple bonds or heteroatomes, A represents a cyclic group, m is an integer from 0 to 7 inclusive, the group(s) R4 is (are) as defined in the description, R3 represents a group selected from hydrogen, alkyl, alkenyl, alkynyl, and the group of formula: in which p, Z2, B, q, and R13 are as defined in the description, optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its the pharmaceutically acceptable salts thereofType: GrantFiled: February 14, 2002Date of Patent: February 1, 2005Assignee: Warner-Lambert CompanyInventors: Charles Andrianjara, Francine Breuzard, Bernard Gaudilliere, Henri Jacobelli
-
Patent number: 6828315Abstract: The present invention relates to triazolo[4,3-a]quinazoline-5-ones and 5-thiones of Formula I and Formula II, whereby I and II are position isomers of group R on nitrogen 3 or 4. Optionally, the invention also relates to the racemic forms, isomers and pharmaceutically acceptable salts thereof. The invention further relates to a method for the production thereof and to compositions containing said derivatives.Type: GrantFiled: October 25, 2001Date of Patent: December 7, 2004Assignee: Warner-Lambert LLCInventors: Bernard Gaudilliere, Remi Lavalette, Charles Andrianjara, Francine Breuzard
-
Patent number: 6787554Abstract: The invention relates to triazolo[4,3-a]pyrido[2,3-d]pyrimidine-5-one derivatives, their regioisomers, their salts and their solvates if they exist, their preparation, compositions containing them and their use. These derivatives possess properties inhibiting PDE4 and/or the release of TNF&agr;, and may therefore be used for the treatment or prevention of numerous conditions by virtue of the inhibition of the PDE4 enzyme and the resulting increase in the cAMP level.Type: GrantFiled: November 22, 2002Date of Patent: September 7, 2004Assignee: Warner-Lambert LLCInventor: Bernard Gaudillière
-
Publication number: 20040006077Abstract: The specification discloses compounds selected from those of formula (I): 1Type: ApplicationFiled: June 24, 2003Publication date: January 8, 2004Inventors: Bernard Gaudilliere, Henri Jacobelli
-
Publication number: 20030220355Abstract: A compound selected from those of formula (I): 1Type: ApplicationFiled: April 16, 2003Publication date: November 27, 2003Inventors: Bernard Gaudilliere, Henry Jacobelli, Catherine Kostlan, Jie Jack Li, Wen-Song Yue
-
Publication number: 20030216402Abstract: A compound selected from those of formula (I): 1Type: ApplicationFiled: March 7, 2003Publication date: November 20, 2003Inventors: Bernard Gaudilliere, Henry Jacobelli, Catherine Kostlan, Jack Jie Li, Wen-Song Yue
-
Publication number: 20030187257Abstract: The invention relates to triazolo[4,3-a]pyrido[2,3-d]pyrimidine-5-one derivatives, their regioisomers, their salts and their solvates if they exist, their preparation, compositions containing them and their use. These derivatives possess properties inhibiting PDE4 and/or the release of TNF&agr;, and may therefore be used for the treatment or prevention of numerous conditions by virtue of the inhibition of the PDE4 enzyme and the resulting increase in the cAMP level.Type: ApplicationFiled: November 22, 2002Publication date: October 2, 2003Inventor: Bernard Gaudilliere
-
Publication number: 20030130278Abstract: A compound selected from those of formula (I): 1Type: ApplicationFiled: October 11, 2002Publication date: July 10, 2003Inventors: Bernard Gaudilliere, Henri Jacobelli, Joseph Armand Picard, Michael William Wilson
-
Publication number: 20020193377Abstract: A compound selected from those of formula (I): 1Type: ApplicationFiled: February 13, 2002Publication date: December 19, 2002Inventors: Charles Andrianjara, Nicole Chantel Barvian, Bernard Gaudilliere, Henri Jacobelli, Daniel Fred Ortwine, William Chester Patt, Ly Pham, Catherine Rose Kostlan, Michael William Wilson
-
Publication number: 20020151558Abstract: A compound selected from those of formula (I): 1Type: ApplicationFiled: February 14, 2002Publication date: October 17, 2002Inventors: Charles Andrianjara, Francine Breuzard, Bernard Gaudilliere, Henri Jacobelli
-
Patent number: 6239130Abstract: The present invention presents compounds that inhibit phosphodiesterase 4 having Formula (I). The present invention also provides methods of using the compounds of Formula (I) to prevent or treat asthma, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disorders, pulmonary hypertension, liver injury, bone loss, septic shock, or multiple sclerosis, and to pharmaceutical compositions that contain the compounds of Formula (I).Type: GrantFiled: November 10, 1999Date of Patent: May 29, 2001Assignee: Warner-Lambert CompanyInventors: Yves Pascal, Catherine Burnouf, Bernard Gaudilliere, Henry Jacobelli, Alain Calvet, Adrian Payne, Svein Dahl
-
Patent number: 5023266Abstract: Ifenprodil and its analogues are useful for the treatment of psychoses such as schizophrenia.Type: GrantFiled: January 24, 1990Date of Patent: June 11, 1991Assignee: SynthelaboInventors: Salomon Z. Langer, Jonathan R. Frost, Johannes Schoemaker, Bernard Gaudilliere, Jean Bertin, Jean Rousseau, Regis Dupont, Alexander E. Wick
-
Patent number: 4950670Abstract: A pyrimidinedione derivative which is a compound of formula (I): ##STR1## in which: R1 denotes hydrogen, a halogen, a methyl group or a methoxy group,R2 denotes hydrogen, a C.sub.1 -C.sub.4 alkyl group or a benzyl group,n denotes 2, 3 or 4,X denotes a CH group or nitrogen, andR3 denotes hydrogen, a halogen or a methoxy group when X denotes a CH group, with the proviso that R3 denotes hydrogen when X denotes nitrogen,or a pharmacologically acceptable acid addition salt thereof.Type: GrantFiled: May 16, 1989Date of Patent: August 21, 1990Assignee: SynthelaboInventors: Jonathan Frost, Bernard Gaudilliere, Jean Rousseau, Regis Dupont, Philippe Manoury, Daniel Obitz
-
Patent number: 4711899Abstract: Compound of general formula I ##STR1## in which R is hydrogen, R.sub.1 is unsubstituted phenyl, 4-methoxy - 3,5-dimethylphenyl or phenyl substituted at one of the 2-, 3- or 4- positions by halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, benzyloxy, trifluoromethyl, cyano, nitro, amino, acetylamino, methylthio, methylsulphonyl or aminosulphonyl and R.sub.2 is unsubstituted phenyl, 2,4,6-trimethoxyphenyl or phenyl substituted at either the 3- or the 4- positions by fluorine, chlorine, methyl or methoxy, or an acid addition salt thereof.Type: GrantFiled: May 13, 1986Date of Patent: December 8, 1987Assignee: SynthelaboInventors: Bernard Gaudilliere, Jean Rousseau
-
Patent number: 4690931Abstract: Compounds of the formula: ##STR1## wherein R.sub.1 is hydrogen, halogen, trifluoromethyl, alkyl, hydroxyl, alkyoxy, benzyloxy, alkanoyloxy, or benzoyloxy, or when R.sub.2 is hydroxyl or methoxy in the 4-position and R.sub.3 is hydrogen, R.sub.1 may also represent hydroxymethyl carbamoyl or alkoxycarbonyl,R.sub.2 is hydrogen, halogen, alkyl, hydroxyl, or alkoxy,R.sub.3 is hydrogen or alkyl,R.sub.4 is alkyl (in which case the compounds are (.+-.)-erythro) or when R.sub.3 represents hydrogen, R.sub.4 may also be hydrogen, and R.sub.5 is hydrogen, halogen, alkyl, alkoxy, or three methoxy groups in the 3-, 4- and 5-positions and pharmaceutically acceptable acid addition salts thereof, with the exclusion of compounds wherein:(a) one of R.sub.1 and R.sub.2 is in the 4-position and is hydroxyl, alkoxy or benzyloxy, the other is in the 3-position and is hydrogen, hydroxyl, alkoxy or benzyloxy, and R.sub.3 and R.sub.5 are hydrogen and wherein:(b) R.sub.1 is in the 4-position and is halogen, R.sub.4 is methyl and R.sub.Type: GrantFiled: September 9, 1985Date of Patent: September 1, 1987Assignee: SynthelaboInventors: Alexander Wick, Jonathan Frost, Bernard Gaudilliere, Jean Bertin, Regis Dupont, Jean Rousseau
-
Patent number: 4223039Abstract: There are provided compounds of the general formula ##STR1## in which Ar represents a phenyl group which is unsubstituted or substituted by a halogen atom or a lower alkyl group, or represents a thienyl group, R.sub.1 represents a hydrogen or halogen atom or, when the Ar--CO-- grouping is in the meta-position with respect to the nitrogen atom, a lower alkyl group, R.sub.2 represents a hydrogen atom, or a lower alkyl or an acyl group, and R.sub.3 represents a hydrogen atom, a lower alkyl or a phenyl group and a physiologically acceptable salt thereof.The compounds of the general formula I and their salts have therapeutic utility, especially as analgesics.Type: GrantFiled: March 14, 1979Date of Patent: September 16, 1980Assignee: Metabio JoullieInventors: Francis E. E. Rose, Christian J. M. Warolin, Pierre Muller, Paul M. P. Fabiani, Bernard Gaudilliere